Founded in Cambridge in 1998, biotech firm Abcam made a name for itself producing high-quality, validated antibodies for ...

This interesting study presents valuable information on how human cytomegalovirus (HCMV) infection disrupts the activity of the TEAD1 transcription factor, leading to widespread chromatin alterations.

In conclusion, by identifying PEBP1 as an amplifier of mitochondrial stress signals, our study provides new insights into cytoplasmic mechanisms which ensure appropriate responses to acute ...

Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced the appointment of Jonathan Milner, Ph.D., as the new non-executive chairman of the board, effective ...

The founder of Abcam, Jonathan Milner, transformed the way scientists access antibodies. Under his leadership as chief executive officer (CEO) until 2014, Abcam grew into a multinational entity with a ...

Immunohistochemical staining using anti-MxA (clone M143; Millipore), anti-integrin alpha4 beta7 (clone 111D9.03; Novus Biologicals) and anti-MAdCAM1 (clone ab307734; Abcam) were applied ... in ...

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

And that has driven a great deal by monoclonal antibodies that are commercialized and where we of course have a very strong position. As we think about smaller customers, so again customers who ...